Log In
Print
BCIQ
Print
Print this Print this
 

Xalkori, crizotinib (PF-02341066)

Also known as: PF-2341066

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionDual inhibitor of c-Met receptor tyrosine kinase and anaplastic lymphoma kinase (ALK) and their oncogenic variants
Molecular Target c-Met receptor tyrosine kinase ; Anaplastic lymphoma kinase (ALK)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor; c-Met receptor tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today